Analyst Price Targets — ALT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 27, 2026 9:11 pm | — | Barclays | $20.00 | $6.18 | TheFly | Altimmune initiated with an Overweight at Barclays |
| April 2, 2024 6:42 am | Patrick Trucchio | H.C. Wainwright | $12.00 | $10.23 | StreetInsider | Altimmune (ALT) PT Lowered to $12 at H.C. Wainwright following Q4 report |
| December 1, 2022 5:36 am | — | Goldman Sachs | $20.00 | $9.95 | Benzinga | Goldman Sachs Initiates Coverage On Altimmune with Buy Rating, Announces Price Target of $20 |
| November 11, 2022 8:29 am | — | JMP Securities | $26.00 | $11.12 | Benzinga | JMP Securities Maintains Market Outperform on Altimmune, Lowers Price Target to $26 |
| August 31, 2022 11:00 am | — | Jefferies | $35.00 | $22.08 | Benzinga | Jefferies Maintains Buy on Altimmune, Raises Price Target to $35 |
| August 30, 2022 8:40 pm | Yasmeen Rahimi | Piper Sandler | $25.00 | $18.94 | TheFly | Altimmune management confident on NAFLD Phase 1b study, says Piper Sandler |
| August 17, 2022 6:36 am | — | H.C. Wainwright | $50.00 | $17.66 | Benzinga | HC Wainwright & Co. Maintains Buy on Altimmune, Raises Price Target to $50 |
Latest News for ALT
ALT5's core fintech platform continued to scale in 2025, supported by growth across payments, trading, and settlement processing of approximately $3.5 billion in transaction volume during the year ALT5 strengthened its operating foundation through compliance restoration, governance upgrades, and continued platform expansion following the acquisition of Mswipe Recent initiatives demonstrate the Company's strategy to…
TNF Pharmaceuticals (NASDAQ: TNFA - Get Free Report) and Altimmune (NASDAQ: ALT - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability. Risk and Volatility TNF Pharmaceuticals has a beta
Altimmune heads into a pivotal 2026 MASH race, betting its dual agonist pemvidutide can stand out in a crowded field as key catalysts and risks converge.
Altimmune heads into 2026 with high-stakes catalysts as pemvidutide drives its pipeline, but funding needs and dilution risk loom alongside key clinical readouts.
Altimmune's pemvidutide targets MASH with dual glucagon/GLP-1 biology, showing mid-stage promise as it advances toward a high-stakes phase III study.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ALT.
U.S. House Trading
No House trades found for ALT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.